Literature DB >> 23410503

Anti-cytokine therapy in the treatment of psoriasis.

Erine A Kupetsky1, Alicia R Mathers, Laura K Ferris.   

Abstract

Psoriasis is a chronic, inflammatory skin disease with many associated co-morbidities including diabetes, hypertension, obesity, psoriatic arthritis, and cardiovascular disease. It has long been known that psoriasis is a T cell-mediate disease and recent findings further demonstrate the important roles of the Th17 and Th22 arms of the immune system in the pathogenesis of psoriasis. Our understanding of this disease has progressed greatly and agents that target the cytokines involved in disease activity are under development or currently being used to treat psoriasis. A comprehensive review of the literature for cytokine-targeted therapies, their safety concerns, and efficacy in psoriasis are discussed here.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410503     DOI: 10.1016/j.cyto.2012.12.027

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  16 in total

1.  MiR-548a-3p Promotes Keratinocyte Proliferation Targeting PPP3R1 after Being Induced by IL-22.

Authors:  Xintong Zhao; Ronghua Li; Meng Qiao; Jianjun Yan; Qing Sun
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

2.  Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis.

Authors:  Ruru Guo; Ting Zhang; Xinyu Meng; Zhen Lin; Jinran Lin; Yu Gong; Xuesong Liu; Yuetian Yu; Guilin Zhao; Xianting Ding; Xiaoxiang Chen; Liangjing Lu
Journal:  JCI Insight       Date:  2019-03-21

3.  Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.

Authors:  Andreas Ritzén; Morten D Sørensen; Kevin N Dack; Daniel R Greve; Anders Jerre; Martin A Carnerup; Klaus A Rytved; Jesper Bagger-Bahnsen
Journal:  ACS Med Chem Lett       Date:  2016-04-14       Impact factor: 4.345

4.  A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis.

Authors:  Benjamin Ungar; Ana B Pavel; Philip M Robson; Audrey Kaufman; Alison Pruzan; Patrick Brunner; Shivani Kaushik; James G Krueger; Mark G Lebwohl; Venkatesh Mani; Zahi A Fayad; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-25

Review 5.  The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.

Authors:  Patrick M Brunner; Emma Guttman-Yassky; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2017-04       Impact factor: 10.793

Review 6.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

7.  Circulating miR-455-3p, miR-5787, and miR-548a-3p as potential noninvasive biomarkers in the diagnosis of acute graft-versus-host disease: a validation study.

Authors:  Jamshid Motaei; Mohammad Amin Kerachian; Seied Asadollah Mousavi; Kamran Alimoghadam; Ardeshir Ghavamzadeh; Saba Manoochehrabadi; Mohammad Ahmadvand; Marjan Yaghmaie
Journal:  Ann Hematol       Date:  2021-07-11       Impact factor: 3.673

8.  Burn wound γδ T-cells support a Th2 and Th17 immune response.

Authors:  Meenakshi Rani; Qiong Zhang; Martin G Schwacha
Journal:  J Burn Care Res       Date:  2014 Jan-Feb       Impact factor: 1.845

Review 9.  The IL-23/IL-17 axis in psoriatic arthritis.

Authors:  Erika Suzuki; Elizabeth D Mellins; M Eric Gershwin; Frank O Nestle; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

10.  TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis.

Authors:  Theodora Chlapanidas; Sara Perteghella; Flavio Leoni; Silvio Faragò; Mario Marazzi; Daniela Rossi; Emanuela Martino; Raffaella Gaggeri; Simona Collina
Journal:  Int J Mol Sci       Date:  2014-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.